Impact of preexisting pulmonary fibrosis detected on chest radiograph and CT on the development of gefitinib-related interstitial lung disease

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 31, Issue 4, 2008, Pages 340-344

  Naito, Yoichi ^a,b   Tsuchiya, Satoshi ^b,c   Ishihara, Shinichi ^b,d   Minato, Koichi ^b,e   Shitara, Yoshinori ^b,f   Takise, Atsushi ^b,g   Suga, Tatsuo ^h   Mogi, Akira ^b,c   Yamabe, Katsumi ^b,d   Saito, Ryusei ^b,d  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b Gunma Lung Cancer Study Group   (Japan)

^c Tsuchiya clinic   (Japan)

^d National Hospital Organization   (Japan)

^e GUNMA PREFECTURAL CANCER CENTER   (Japan)

^f Isesaki Municipal Hospital   (Japan)

^g MAEBASHI RED CROSS HOSPITAL   (Japan)

^h GUNMA UNIVERSITY   (Japan)

Author keywords

Gefitinib; Interstitial lung disease; Nonsmall cell lung cancer; Preexisting fibrosis

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CORTICOSTEROID; GEFITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ACUTE RESPIRATORY FAILURE; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; COURSE EVALUATION; DESQUAMATION; DIARRHEA; DISEASE ASSOCIATION; DRUG ERUPTION; DRUG FATALITY; DRUG INDICATION; DRY SKIN; ERYTHEMA; ESOPHAGITIS; FATIGUE; FEMALE; GASTRITIS; HUMAN; IMAGE ANALYSIS; INFECTION; INTERSTITIAL LUNG DISEASE; LIVER DISEASE; LUNG ADENOCARCINOMA; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; NAIL DISEASE; NAUSEA; RADIOLOGIST; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; THORAX RADIOGRAPHY; ADENOCARCINOMA; DRUG ANTAGONISM; FOLLOW UP; GENETICS; LUNG TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RADIOGRAPHY; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN KINASE INHIBITORS; PULMONARY FIBROSIS; QUINAZOLINES; RADIOGRAPHY, THORACIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 55449115687     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318162f13b     Document Type: Article

References (23)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 2005;128:452-462.
3. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995;311:899-909.
4. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003;21:2237-2246.
5. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290:2149-2158.
6. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366: 1527-1537.
7. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
8. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304:1497-1500.
9. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306-13311.
10. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004;64:8919-8923.
11. Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res. 2004;10:8195-8203.
12. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2005;23:2493-2501.
13. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005;23:2513-2520.
14. Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol. 2006;24:3340-3346.
15. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet. 2003;361:137-139.
16. Ohyanagi F, Ando Y, Nagashima F, et al. Acute gefitinib-related pneumonitis. Int J Clin Oncol. 2004;9:406-409.
17. Hotta K, Kiura K, Tabata M, et al. Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer J. 2005;11:417-424.
18. Takano T, Ohe Y, Kusumoto M, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer. 2004;45:93-104.
19. Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2006;24:2549-2556.
20. AstraZeneca. In-house data; result and discussion document concerning the prospective investigation on Iressa Tablet 250 (Special Investigation). 2004.
21. Niho S, Kubota K, Goto K, et al. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 2006;24:64-69.
22. Cohen MH, Williams GA, Sridhara R, et al. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist. 2003;8:303-306.
23. Kelly K, Gasper LE, Chansky K, et al. Low incidence of pneumonitis on SWOG 0023: a preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III nonsmall cell lung cancer. Proc Am Soc Clin Oncol. 2005;41:Abstr 7058.